Suppliers / Arene Life Sciences

Arene Life Sciences

India 222 employees Updated 9 July 2026

Arene Life Sciences is an API manufacturer based in India. It holds 31 active US drug master files across a filed portfolio of 16 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 30 August 2024 as VAI. Customs aggregates show $7.0M of exports covering 140 molecules to 29 destinations in 2025.

31
active US DMFs
0
valid CEPs
2
registered plants 2 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
2 of 2 confirmed
Inspections
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 30 August 2024 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Nalgonda, India 3033870708
Sangareddy, India 3013438177

What they file, and where

Molecule Regulators Docs
Dolutegravir SFDA (Saudi Arabia), US FDA 3
Amlodipine US FDA 2
Bictegravir US FDA 2
Clopidogrel US FDA 2
Darunavir US FDA 2
Efavirenz US FDA 2
Emtricitabine US FDA 2
Lamivudine US FDA 2
Lopinavir US FDA 2
Nefopam US FDA 2
Show all 16 molecules on file
Oxcarbazepine US FDA 2
Ritonavir US FDA 2
Tedizolid US FDA 2
Tenofovir Alafenamide US FDA 2
Trazodone US FDA 2
Eslicarbazepine Acetate US FDA 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA None 1

Scale

Year Revenue Exports Destinations
2026 YTD Not reported $4.3M 17
2025 Not reported $7.0M 29

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Arene Life Sciences comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 30 August 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts